The IC50 (mean±SEM) values for 5-fluoruracil, oxaliplatin, cisplatin, doxorubicin, paclitaxel, and irinotecan with or without nivolumab treatment in HT29, HCT116, LOVO, SW620, and PES43 cell lines
| HT29 (PD-1: 23%) | HCT116 (PD-1: 31%) | LOVO (PD-1: 22%) | SW620 (PD-1: 15%) | PES43 (PD-1: 20%) | ||||||
| IC50 | RR | IC50 | RR | IC50 | RR | IC50 | RR | IC50 | RR | |
| 5-fluoruracil | 6.1±0.5 | 3.06 | 6.9±1.8 | 2.19 | 1.2±0.2 | 1.92 | 14.8±3.2 | 1.03 | 7.9±2.3 | 1.05 |
| 5-fluoruracil+NIVO | 18.7±5.8 | 15.1±1.5* | 2.3±0.05* | 15.2±3.3 | 8.3±4.3 | |||||
| Oxaliplatin | 9.5±2.2 | 2.76 | 4.4±1.9 | 4.75 | 0.9±0.3 | 15.8 | 1.5±0.2 | 1.53 | 10±1.3 | 1.20 |
| Oxaliplatin +NIVO | 26.2±5.2* | 20.9±0.95** | 14.2±5.9 | 2.3±0.7 | 12±1.4 | |||||
| Cisplatin | 6.1±1.2 | 2.51 | 6.5±0.9 | 2.71 | 6.7±0.7 | 1.8 | 4±1 | 1.75 | 5.5±1.7 | 1.13 |
| Cisplatin+NIVO | 15.3±2.7* | 17.6±7.9 | 12.4±2.0* | 7±1.7 | 6.2±1.0 | |||||
| Doxorubicin | 0.05±0.02 | 60 | 0.05±0.02 | 2 | 0.09±0.05 | 3.5 | 0.4±0.2 | 0.5 | 0.06±0.03 | 0.5 |
| Doxorubicin +NIVO | 3±0.005*** | 0.1±0.08* | 0.3±0.005** | 0.2±0.2 | 0.03±0.02 | |||||
| Paclitaxel | 0.3±0.1 | 12.7 | 0.02±0.01 | 5 | 0.1±0.02 | 23 | 0.3±0.1 | 0.7 | 0.2±0.05 | 0.45 |
| Paclitaxel +NIVO | 3.8±0.05** | 0.1±0.01* | 2.3±0.2* | 0.2±0.1 | 0.09±0.06 | |||||
| Irinotecan | 16.1±2.6 | 2.2 | 7.0±1.1 | 1.7 | 33.1±1.3 | 2.9 | 3.3±1 | 1.3 | 21±3.2 | 1.2 |
| Irinotecan+NIVO | 34.8±2.3* | 11.8±1.3 | 97.9±1.3*** | 4.3±0.2 | 26.3±5.6 | |||||
Statistically significant: *p<0.05; **p<0.01; ***p<0.001.
RR, resistance ratio (IC50 of chemotherapy+NIV/IC50 of chemotherapy).